NNMT and obesity due to melanocortin 4 receptor deficiency: NNMT has been proposed as a pharmacological target for treating obesity and type 2 diabetes based on higher NNMT expression and plasma MNA levels in individuals with obesity or T2D and animal studies using antisense-oligonucleotide mediated knockdown of NNMT3,4,6.